Pharmacological or genetic mTORC2 inhibition in cancer cells induces higher xCT activity and GSH synthesis [7], while cancer cells with hyperactive PI3K signaling become metabolically more vulnerable to methionine deprivation via the inhibition of xCT expression and function [6]. The gene discussed is SLC7A11; the disease is cancer.